` IGX (Intelgenx Technologies Corp) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

IGX
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, IGX has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +28% growth.

Stocks Performance
IGX vs S&P TSX Composite Index (Canada)

Loading
IGX
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IGX vs S&P TSX Composite Index (Canada)

Performance Gap Between IGX and GSPTSE
HIDDEN
Show

Performance By Year
IGX vs S&P TSX Composite Index (Canada)

Loading
IGX
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Intelgenx Technologies Corp vs Peers

S&P TSX Composite Index (Canada)
IGX
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Intelgenx Technologies Corp
Glance View

Market Cap
41.9m CAD
Industry
Pharmaceuticals

IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The company went IPO on 2008-05-23. The firm is focused on the development and manufacturing of pharmaceutical films. The firm's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The firm's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).

IGX Intrinsic Value
Not Available
Back to Top